The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a ...

Other companies are also developing amylin-targeting drugs. Novo Nordisk’s amycretin targets both amylin and GLP-1. Viking Therapeutics, whose pipeline includes both injectable and oral agonists ...

Ascletis announces positive results from US phase Ia SAD study of small molecule oral GLP-1R agonist ASC30 in patients with obesity: Hong Kong, China Wednesday, January 22, 2025, ...

Oral delivery of drugs requires far higher quantities of ... its 12-week human study already underway in Australia (study GLP-1-H24-4). In that study arm, oral DehydraTECH-tirzepatide will be ...

Laxxon Medical reports positive results from pilot PK study of innovative oral GLP-1 agonist weight loss tablet, LXM.2 ...

Lexaria Bioscience (LEXX) announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study ...

s leading glucagon-like peptide-1 / glucose-dependent insulinotropic (GLP-1/GIP) drugs. Furthermore, the oral DehydraTECH-tirzepatide evidenced a comparable overall reduction in blood glucose from ...

Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria ...